OSS, THE NETHERLANDS, November 23, 2021 /EINPresswire.com/ — Osteo-Pharma today announced that the first patient has been treated for the clinical trial ‘OsteoActivator-P for accelerated localized alveolar ridge preservation’. The study is a randomized...
AMSTERDAM, November 17, 2021 (Newswire.com) – Emultech and Osteo-Pharma today announced a joint venture to develop what could be the first disease-modifying treatment for osteoarthritis of the knee. The joint venture, to be called Bone-Tech, brings together...
Osteo-Pharma Release: Osteo-Pharma today announced that it has successfully obtained MREC approval for testing their lead product, OsteoActivator-P, in patients. OsteoActivator-P is a novel coated porcine collagen barrier membrane that will be placed on a dental...
Osteo-Pharma Release: Osteo-Pharma, a Dutch Life Sciences company developing novel pharmaceuticals and medical devices to improve the local healing of bone fractures and defects, today has announced that it has successfully completed a large preclinical study in...
Osteo-Pharma BV announced today that it received formal notice that the European Patent Office’s Examining Division issued the formal notification of intention to grant the Osteo-Pharma patent application titled “Compositions and products for use in the treatment of...
